Core Viewpoint - Changchun High-tech has over 40 candidate drugs in clinical stages or submitted for IND applications, with significant advancements in its pipeline expected by late 2025 [2] Group 1 - As of the last feasible date of the company's prospectus (late September 2025), it has more than 40 candidate drugs in clinical stages or submitted for IND applications [2] - Among these, there are 14 candidates in Phase III clinical trials or new drug application (NDA) stages, and 15 first-class innovative drugs [2] - The company advises stakeholders to refer to its subsequent annual reports for accurate disclosures by the end of 2025 and to check previous announcements for recent clinical progress of key innovative products [2]

Group 1 - The company, Changchun High-tech (000661), responded to investor inquiries on January 9, indicating that different companies have varying research and development (R&D) paths, deployment rhythms, and investment timelines [1] - The company emphasized that the value of technical barriers in specific fields should not be simply measured by quantity [1]

Group 1 - The company was asked by investors if its medical-grade PEG can be applied in brain-machine engineering [2] - The company responded that the PEG-related materials produced by its subsidiary are currently mainly used in its long-acting growth hormone products [2]

Group 1 - The company is one of the few domestic manufacturers of high-purity polyethylene glycol (PEG) raw materials for medical use, with a comprehensive range of products that can be developed and produced according to customer needs [2] - The PEG-related raw materials produced by the company's subsidiary are primarily used in the company's long-acting growth hormone products [2]

Group 1 - Jinli Permanent Magnet expects a net profit of 660 million to 760 million yuan for 2025, representing a year-on-year growth of 127% to 161% [1] - Wens Foodstuffs anticipates a net profit of 5 billion to 5.5 billion yuan for 2025, a decrease of 40.73% to 46.12% compared to the previous year [2] - New Open Source plans to repurchase shares worth 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [3] Group 2 - Fosun Pharma's subsidiary has had a drug registration application accepted for a new drug targeting ALK-positive non-small cell lung cancer [4] - Leike Film reported a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [5] - Crown Stone Technology's application for a specific issuance of A-shares has been accepted by the Shanghai Stock Exchange [6] Group 3 - Dongxin Technology has completed the business registration change for its subsidiary, Lishuan Technology, and has invested 211 million yuan in it [7] - Tianci Materials has increased its commodity futures hedging business limit from 150 million to 300 million yuan [8] - Gaode Infrared's actual controller has reduced his shareholding by 0.54%, bringing his stake down to 62.95% [9] Group 4 - Tianyong Intelligent expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [10][11] - China Merchants Energy anticipates a net profit of 6 billion to 6.6 billion yuan for 2025, an increase of 17% to 29% year-on-year [18] - Guangdong Electric Power A's Huizhou Power Plant's Unit 5 has been put into commercial operation, with an investment of 8.05 billion yuan [19] Group 5 - Jianghuai Automobile reported a 42.24% year-on-year increase in sales volume for December 2025 [25] - China Pharmaceutical's subsidiary has received a drug registration certificate for a new medication [26] - TianNeng Co. plans to use up to 12 billion yuan of its own funds for entrusted wealth management [27] Group 6 - Luoyang Huizhong reported a 10.55% month-on-month decrease in sales revenue from live pigs for December 2025 [28] - Baolidi expects a net profit of 145 million to 152 million yuan for 2025, a year-on-year increase of 27.17% to 33.30% [30] - Changchun High-tech's subsidiary has had a melatonin granule registration application accepted [31] Group 7 - Zhongmin Energy reported a 4.46% year-on-year decrease in cumulative on-grid electricity for 2025 [32] - Huaxin Electronics reported a 7.79% year-on-year decrease in consolidated operating revenue for December 2025 [35] - Xiamen Airport reported a 2.79% year-on-year increase in passenger throughput for December 2025 [36] Group 8 - Baiyun Airport reported a 12.27% year-on-year increase in passenger throughput for December 2025 [37] - Pulaike has received a new veterinary drug registration certificate for a chewable tablet [38] - Yunnan Energy Holdings' subsidiary has reduced its stake to 84% after a capital increase [39] Group 9 - Gansu Energy Chemical's new thermal power project has successfully completed trial operation [41] - Zhenghong Technology reported a significant decrease in sales revenue from live pigs for December 2025 [42] - Huasheng Lithium Battery is planning to issue H-shares for listing on the Hong Kong Stock Exchange [43] Group 10 - Jincheng Mining has signed a mining production contract with an estimated total price of approximately 510 million yuan [44] - Microchip Biotech has received approval for clinical trials of a new drug for pancreatic cancer [45] - Yahon Pharmaceutical has completed the first patient enrollment for a Phase I clinical trial of its drug [46]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of its injectable GenSci136, a first-class therapeutic biological product developed in-house, aimed at treating Immunoglobulin A Nephropathy (IgAN) [1] Group 1 - Jinsai Pharmaceutical's injectable GenSci136 is a first-class therapeutic biological product developed for the treatment of IgAN [1] - GenSci136 is a B-cell maturation antigen (BCMA) trimeric fusion protein that can bind to B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL) [1] - The drug has the potential to treat various autoimmune diseases characterized by tissue damage caused by pathogenic antibodies, by affecting the survival and differentiation of B lymphocytes and plasma cells [1]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the domestic production drug registration application of melatonin granules, indicating progress in the approval process for this product [1][1]. Group 1 - Jinsai Pharmaceutical's melatonin granules are developed for the pediatric neuropsychiatric field and classified as a Class 4 chemical drug [1]. - The product is designed to activate the MT1 and MT2 receptors in the suprachiasmatic nucleus, which regulates neural activity and demonstrates sleep-inducing effects [1]. - The intended use of the melatonin granules is to improve sleep difficulties associated with neurodevelopmental disorders in children [1].

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of its injectable GenSci136, aimed at treating Immunoglobulin A Nephropathy (IgAN) [1] Group 1 - The clinical trial application for GenSci136 has been accepted, indicating progress in the drug development process [1] - The targeted indication for GenSci136 is Immunoglobulin A Nephropathy (IgAN), a significant condition that may present a market opportunity [1]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the domestic production drug registration application of melatonin granules, indicating progress in its product development in the pediatric neuropsychiatric field [1]. Group 1 - The melatonin granules are developed by Jinsai Pharmaceutical and are classified as a Category 4 chemical drug [1]. - The product aims to improve sleep difficulties associated with neurodevelopmental disorders in children by activating the MT1 and MT2 receptors in the suprachiasmatic nucleus [1]. - The indication for the product is specifically targeted at children experiencing sleep onset issues due to neurodevelopmental disorders [1].

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of its injectable GenSci136, aimed at treating Immunoglobulin A Nephropathy (IgAN) [1] Group 1 - The clinical trial application for GenSci136 has been accepted, indicating progress in the drug development process [1] - The targeted indication for GenSci136 is Immunoglobulin A Nephropathy (IgAN), a significant condition affecting kidney function [1]